📌 Key Takeaways
- Topic: Aerosil Alternative: Equivalent Fumed Silica Grades and How to Switch
- Keywords: silica free flow agent
- Published: 2026-11-20 02:05:56
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Supplier Mexico: Sourcing Options, Producers and Import Tips
- Silica for Solar Crucible: Purity Standards and Supply Considerations
- Mesoporous silica nanoparticles (MSNs) are a flexible platform for the improvement of water solubility and bioavailability of poorly water-soluble drugs through the stabilization of the API in the amorphous state. Two outstanding mechanisms facilitate such stabilization: physical entrapment within nanoscale pores with a diameter less than the size of the critical nucleus. In this case, the ordered molecular packing necessary to develop crystals cannot advance. Moreover, the unique interactions between the functional groups of APIs and the surface silanol groups of MSNs may immobilize drug molecules at or close to pore walls [ 44, 45 ]. Bavnhøj et al. used celecoxib to demonstrate that when loading is conducted under the pore-filling ability (PFC) of the silica matrix, the drug will be physically stable and amorphous for at least 18 months of dry storage. PFC-loaded along with near-PFC-loaded samples recrystallized, especially upon exposure to moisture, demonstrating the razor-thin margin between the level of loading and stability [ 46 ]. Although advantages are present, long-term stability is undermined by stress recrystallization. For example, α-mangostin began to recrystallize after 7-14 days at 25 °C and 95% relative humidity in MSNs with slightly broader pore size than the molecular size of the API, indicating that pore size must be finely tuned for productive confinement [ 47 ]. Similarly, simvastatin had the longest amorphous lifespan when loaded into pores of 4.5 nm. Still, it exhibited rapid recrystallization in materials with bigger pore size, underlining the critical importance of pore size for the preservation of amorphous stability [ 45, 47 ].
- Nano Silica Supplier: How to Verify Particle Size, Purity and Consistency
- 41. Elmowafy M., Alruwaili N.K., Ahmad N., Kassem A.M., Ibrahim M.F. Quercetin-Loaded Mesoporous Silica Nanoparticle-Based Lyophilized Tablets for Boosted Physicochemical Features and Dissolution Rate: Formulation, Optimization, and In Vitro Evaluation. AAPS PharmSciTech. 2023;24:6. doi: 10.1208/s12249-022-02464-w. [ DOI ] [ PubMed ] [ Google Scholar ]
- Angular Silica Powder: Properties, Uses and When to Choose It Over Spherical Silica
- Amorphous vs Crystalline Silica: Structure, Safety and Uses Compared
Silicon Oxide Anode (SiOx): How It Works and Its Advantages for Lithium-Ion Batteries
What is silica (SiO₂)?
fused silica sand
What is the difference between fumed silica and precipitated silica?
silica for silicone rubber
What drives silica raw material prices?
silica particle size Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.